Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
Status:
Not yet recruiting
Trial end date:
2022-08-30
Target enrollment:
Participant gender:
Summary
This is an open-label Phase I clinical study that will administer a single dose of 186RNL via
intraventricular catheter for treatment of Leptomeningeal Metastases (LM).